Bird & Bird's private equity practice supports sponsors, management teams and institutional investors with buy-out transactions, particularly in regulated and innovation-driven sectors. Co-led by corporate specialists Emmanuelle Porte and Carole Bodin, the team acts in primary and secondary LBOs, MBOs, build-ups, exits and reinvestments, and regularly advises on management incentive packages and shareholder structuring.
Legal 500 Editorial commentary
Accolades
Client satisfaction: NPS ®
Testimonials
Collated independently by Legal 500 research team.
- ‘Rigour and pragmatism in handling cases. Knowledge of practices. Negotiation skills.’
Key clients
- ARM Sparing Vision Infravia Growth Caisse des dépôts et consignations Enterome Coave Therapeutics Efeso Consulting Group Bpifrance Investissement Engie New Ventures St-Hubert Qwant GEI Cryocollect Isalt Tibbloc Alto Finances AGS Therapeutics Bordeaux River Cruise Sydev Semtech Fosun Solar Eclipse Galaxy Brainever Capital Croissance Adaxtra Biomemory Mirsense
Work highlights
Advising Bpifrance Large Venture on its participation in the $41m Series A financing round of Bioptimus, a biotech company wishing to develop a specialised generative AI model for biology.
Advising the lead investors Business Opportunities for L'Oreal Development, DTCF, Evonik and Clay Capital in the series A financing round of Abolis Biotechnology, a French company specialising in the development of microbial strains and production methods for industrial use.
Advising BrainEver, a French biotech company specialised in the development of new therapies for patients with age-related neurodegenerative diseases, on its €33m Series B fundraising round to fight Charcot's disease.
Practice head
Emmanuelle Porte; Carole Bodin
Other key lawyers
Gildas Louvel; David Malcoiffe; Bertrand Levy; Félicien Bardsley; Olivier Peronnau; Lionel Berthelet; Sonia Sassi